[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640764":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":17,"centralContacts":24,"locations":30,"responsibleParty":47,"collaborators":17,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":17,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":17,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":17,"overallStatus":70,"whyStopped":17,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Shanghai Zhongshan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"anticoagulant group","EXPERIMENTAL","Rivaroxaban 10mg qd po. for 6 months",[13],"Drug: Rivaroxaban",{"label":15,"type":16,"description":17,"interventionNames":17},"control group","NO_INTERVENTION",null,[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":17},"DRUG","Rivaroxaban","Rivaroxaban 10mg qd po for 6 months",[9],[25],{"name":26,"role":27,"phone":28,"phoneExt":17,"email":29},"Shiyao Chen Prof.","CONTACT","+86+‭136 0176 7310‬","chen.shiyao@zs-hospital.sh.cn",[31],{"facility":32,"status":17,"city":33,"state":17,"zip":17,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Dr. Huang xiaoquan","Shanghai","China","CN",{"type":37,"coordinates":38},"Point",[39,40],121.45806,31.22222,{"lat":40,"lon":39},[43],{"name":44,"role":27,"phone":45,"phoneExt":17,"email":46},"xiaoquan Huang Dr.","+86+‭18801733835","huang.xiaoquan@zs-hospital.sh.cn",{"type":48,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100640764","direct-oral-novel-anticoagulants-for-patients-with-high-risk-gastroesophageal-variceal-bleeding-and-portal-vein-thrombosis-100640764",false,"NCT07602062","Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis","Multicenter Randomized Controlled Clinical Trial on Direct Oral Novel Anticoagulants for Improving the Prognosis of Cirrhotic Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis","Inclusion Criteria:\n\n* Clinical and imaging diagnosis of liver cirrhosis and esophagogastric varices, with at least one previous episode of esophagogastric variceal bleeding\n* Combined with portal vein thrombosis and D-dimer \\> 0.8mg\u002FL\n* Endoscopic evaluation reveals a high risk of variceal bleeding, and endoscopic treatment is performed to prevent rebleeding of esophagogastric varices\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Received other antithrombotic therapies before (including warfarin, aspirin, low-molecular-weight heparin, etc.)\n* Combined with hepatocellular carcinoma or other malignancy\n* Combined with portal cavernoma\n* Combined with severe life-threatening diseases of circulatory, hematological and respiratory system\n* Combined with diseases requiring anticoagulant therapy, such as acute portal vein thrombosis, atrial fibrillation, lower extremity venous thrombosis, and pulmonary embolism\n* Received TIPS or liver transplantation or splenectomy\n* With contraindications to anticoagulant therapy (uncontrollable active bleeding, severe hepatic insufficiency, renal insufficiency, etc.)\n* Currently taking immunosuppressive agents, or medications that affect cytochrome P450 (including azole antifungals and protease inhibitors), or strong inducers of CYP3A4 (including rifampicin, phenytoin, carbamazepine, etc.)","ALL","18 Years","75 Years",{"count":60,"type":61},175,"ESTIMATED","INTERVENTIONAL",[64],"NA","This study aims to explore the safety and efficacy of oral administration of a novel anticoagulant (rivaroxaban) in patients with cirrhosis accompanied by high-risk esophagogastric variceal bleeding and portal vein thrombosis, through a prospective, multicenter, randomized controlled clinical trial, starting 48 hours after endoscopic treatment to prevent rebleeding.",[67,68,69],"Portal Vein Thrombosis","Anticoagulant Therapy","Variceal Bleeding","NOT_YET_RECRUITING","2026-05-16",{"date":73,"type":74},"2026-05-22","ACTUAL",{"date":76,"type":61},"2026-06-01",{"date":78,"type":61},"2027-12-31",{"name":5,"class":6},1]